BioCentury
ARTICLE | Clinical News

RHB-103 regulatory update

November 19, 2012 8:00 AM UTC

RedHill said it and partner IntelGenx plan to submit an NDA to FDA next quarter for RHB-103 to treat migraine based on a pre-NDA meeting with the agency. RedHill has exclusive, worldwide rights to co-...